e petition and thus FDA's 
conclusions should have referred to the eligibility of sucralose-based 
sugar substitute formulations generically. The petitioner further noted 
that SPLENDA brand name product formulations can be changed and may in 
the future meet Sec.  101.80(c)(2)(iii) eligibility criteria.
    (Response) The petition cites dental plaque pH studies conducted 
with sucralose-based formulations representative of commercially 
marketed SPLENDA sugar substitute products. FDA discussed these